Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AbbVie Prices Oral Endometriosis Drug Orilissa In Value Range, Focusing On Access

Jul 24 2018

• By Emily Hayes

Female uterus and ovaries abstract background.

Related Content

AbbVie’s Gaps Are Neurocrine’s Gains

Feb 12 2013

Keeping Track: FDA Delays Elagolix, Mylan Eyes For Neulasta Biosimilar Approval, And Duvelisib Gets Priority Review

Apr 15 2018

Liver Damage Worries Lead To Further EU Restrictions On Richter’s Esmya

May 21 2018

AbbVie's Got A Competitive Edge With Elagolix For Women With Uterine Fibroids

Feb 21 2018

AbbVie's Elagolix May Be Cost Effective, But Will Test Health Budgets – ICER

Jun 18 2018

Related Companies

AbbVie Inc.

Neurocrine Biosciences, Inc.

Gedeon Richter Plc.

Allergan plc

Roivant Sciences Ltd.

ObsEva SA

Kissei Pharmaceutical Co., Ltd

Additional Topics

Approvals Research & Development FDA Gynecology & Urology BioPharmaceutical

More from New Products

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window